Navigation Links
InterMune Reports Fourth Quarter and Full Year 2009 Financial Results and Business Highlights
Date:2/17/2010

ermune.com">www.intermune.com.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of section 21E of the Securities Exchange Act of 1934, as amended, that reflect InterMune's judgment and involve risks and uncertainties as of the date of this release, including without limitation the statements related to anticipated product development timelines and the likelihood of regulatory success. All forward-looking statements and other information included in this press release are based on information available to InterMune as of the date hereof, and InterMune assumes no obligation to update any such forward-looking statements or information. InterMune's actual results could differ materially from those described in InterMune's forward-looking statements.  Pirfenidone failed to achieve statistical significance on the primary endpoint in one of its two pivotal clinical trials and there can be no assurance that the regulatory authorities in either the United States or Europe will grant regulatory approval based upon these data, in combination with the other efficacy and safety results the company has submitted in support of its NDA filing and currently intends to submit in support of its MAA filing.

Other factors that could cause or contribute to such differences include, but are not limited to, those discussed in detail under the heading "Risk Factors" attached as Exhibit 99.3 to InterMune's Form 8-K filed with the SEC on January 20, 2010, and other periodic reports filed with the SEC, including the following: (i) the fact that physician prescriptions of Actimmune for the treatment of IPF, an indication for which Actimmune has not been approved by the FDA, have declined significantly following the March 2007 termination of the Phase 3 INSPIRE trial
'/>"/>

SOURCE InterMune, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. InterMune Announces Approval of Clinical Trial Authorization for Phase 1b Trial of ITMN-191
2. InterMune Announces Start of Phase 1b Trial of ITMN-191
3. InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update
4. InterMune Provides Additional Information on ITMN-191 (R7227) MAD Study Results
5. InterMune Announces Progress on Pirfenidone in IPF
6. InterMune Announces Receipt of Fast Track Designation for Pirfenidone From FDA
7. InterMune Announces Start of 14-Day Triple Combination Study of ITMN-191 in Patients With Chronic Hepatitis C
8. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
9. InterMune to Report Top-Line Results of Triple Combination Study of ITMN-191 in January 2009
10. InterMune to Conduct Conference Call and Webcast to Discuss Results of Triple Combination Study of ITMN-191
11. InterMune to Announce Results of Phase 3 CAPACITY Program of Pirfenidone in IPF Tomorrow, February 3
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... 2015 Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ... million for the three months ended March 31, 2015 ... $22.6 million for the same period in 2014.  Isis, ... from milestone payments earned from its partners compared to ... Isis reported a loss from operations of $9.3 million ...
(Date:5/5/2015)... PORTLAND, Oregon , May 5, 2015 ... market in the US, Europe , ( ... , Spain , UK) and ... and etiology are reviewed. The report provides the 5-year test volume ... Ag, HCV, HCV NAT, Anti-HBc, Anti-HBs, Anti-HAV, Hepatitis Delta, HBc Ag, ...
(Date:5/5/2015)... May 5, 2015  Image Stream Medical, a leader ... with MedAssets, one of the largest group purchasing organizations, ... States.  Under terms of the three-year agreement, Image Stream,s ... will be made available to MedAssets members beginning on ... Image Stream Medical CEO Eddie Mitchell said, ...
Breaking Medicine Technology:Isis Reports Financial Results and Highlights for First Quarter 2015 2Isis Reports Financial Results and Highlights for First Quarter 2015 3Isis Reports Financial Results and Highlights for First Quarter 2015 4Isis Reports Financial Results and Highlights for First Quarter 2015 5Isis Reports Financial Results and Highlights for First Quarter 2015 6Isis Reports Financial Results and Highlights for First Quarter 2015 7Isis Reports Financial Results and Highlights for First Quarter 2015 8Isis Reports Financial Results and Highlights for First Quarter 2015 9Isis Reports Financial Results and Highlights for First Quarter 2015 10Isis Reports Financial Results and Highlights for First Quarter 2015 11Isis Reports Financial Results and Highlights for First Quarter 2015 12Isis Reports Financial Results and Highlights for First Quarter 2015 132015 Opportunities in the Global Hepatitis Diagnostic Testing Market: Big Market Research 22015 Opportunities in the Global Hepatitis Diagnostic Testing Market: Big Market Research 3Image Stream Medical Announces Agreement with MedAssets 2
... Conn., Mar. 14, 2011 Biodel Inc. (Nasdaq: ... two new formulations of recombinant human insulin for clinical ... mealtime insulin drug candidates.  The new formulations, BIOD-105 and ... action compared to currently marketed meal time insulin analogs ...
... Inovio Pharmaceuticals, Inc. (NYSE Amex: INO ), ... vaccines against cancers and infectious diseases, announced today that ... initiated a Phase IIb clinical study of its ChronVac-C® ... Inovio,s proprietary electroporation DNA vaccine delivery technology, in combination ...
Cached Medicine Technology:Biodel Announces Accelerated Development Plan for Ultra-Rapid-Acting Insulins: Initiate Phase 2 in 2011; Phase 3 Pivotal Trials in 2012 2Biodel Announces Accelerated Development Plan for Ultra-Rapid-Acting Insulins: Initiate Phase 2 in 2011; Phase 3 Pivotal Trials in 2012 3Biodel Announces Accelerated Development Plan for Ultra-Rapid-Acting Insulins: Initiate Phase 2 in 2011; Phase 3 Pivotal Trials in 2012 4Biodel Announces Accelerated Development Plan for Ultra-Rapid-Acting Insulins: Initiate Phase 2 in 2011; Phase 3 Pivotal Trials in 2012 5Inovio Pharmaceuticals' Partner ChronTech Initiates Phase II Clinical Trial of Hepatitis C Virus DNA Vaccine Using Inovio's Electroporation Delivery Technology 2Inovio Pharmaceuticals' Partner ChronTech Initiates Phase II Clinical Trial of Hepatitis C Virus DNA Vaccine Using Inovio's Electroporation Delivery Technology 3Inovio Pharmaceuticals' Partner ChronTech Initiates Phase II Clinical Trial of Hepatitis C Virus DNA Vaccine Using Inovio's Electroporation Delivery Technology 4Inovio Pharmaceuticals' Partner ChronTech Initiates Phase II Clinical Trial of Hepatitis C Virus DNA Vaccine Using Inovio's Electroporation Delivery Technology 5
(Date:5/5/2015)... B. E. Smith, the only full-service ... been retained to recruit a new administrator ... executive search firm in the healthcare industry, B. E. ... into organizations. , Shodair Children’s Hospital is the only ... offer both acute and residential inpatient services, as well ...
(Date:5/5/2015)... The PracticeMatch Career Fair will take ... at the Rochester Marriott, 1001 First Avenue SW, Rochester, MN ... opportunities will be attending from across the country. All specialties ... raffle prize drawings. , Leslie Thompson, Director of Career Fairs ... to hold a career fair. In the metropolitan area there ...
(Date:5/5/2015)... May 05, 2015 Atlantic Information ... AIS’s Directory of Health Plans, and other industry-leading ... its new monthly newsletter, AIS’s Value-Based Care News. ... physician groups, pharma companies and their advisers, AIS’s ... medical homes, bundled payments, coordinated care, global payments ...
(Date:5/5/2015)... 05, 2015 The report ... provides comparative analysis on the therapeutic development ... pipelines by identifying new targets and MOAs ... report is available at http://www.rnrmarketresearch.com/liver-fibrosis-pipeline-review-h2-2014-market-report.html ... Fibrosis – Pipeline Review, H2 2014 report ...
(Date:5/5/2015)... 2015 BioFit Engineered Products , ... feature models from its two latest lines at NeoCon ... in Chicago. Headlining the company’s exhibit will be new ... line, as well as the unveiling of the fifth ... president Ed Metzger will deliver in-booth presentations each day ...
Breaking Medicine News(10 mins):Health News:Shodair Children’s Hospital Retains B. E. Smith to Recruit New Administrator 2Health News:Shodair Children’s Hospital Retains B. E. Smith to Recruit New Administrator 3Health News:PracticeMatch to Host Physician Career Fair at the Rochester Marriott on May 12, 2015 2Health News:PracticeMatch to Host Physician Career Fair at the Rochester Marriott on May 12, 2015 3Health News:New AIS Newsletter Features Expert Insights and Strategies on Value-Based Care Arrangements 2Health News:Liver Fibrosis Therapeutic Development and Pipeline Market Review H2 2014 Available at RnRMarketResearch.com 2Health News:Liver Fibrosis Therapeutic Development and Pipeline Market Review H2 2014 Available at RnRMarketResearch.com 3Health News:BioFit to Introduce New Models from Latest Specialized Ergonomic Seating Lines at NeoCon 2015 2Health News:BioFit to Introduce New Models from Latest Specialized Ergonomic Seating Lines at NeoCon 2015 3
... Jazz,Pharmaceuticals, Inc. (Nasdaq: JAZZ ) announced today ... a corporate presentation at the,Morgan Stanley Global Healthcare ... 2008 at 8:00 a.m. Eastern Time., A ... by visiting the,Investors section of the Jazz Pharmaceuticals ...
... develops simple test to identify those at risk ... self-administered test to identify surgical patients who may have ... by a team of Canadian anesthesiologists. , People ... they sleep. The disorder affects 2 percent to 26 ...
... Healthcare Challenges, WELLINGTON, Fla., April 23 ... QGP.WSB) (http://www.QuantumMD.com ) announced today that,Company ... been asked to deliver the,keynote address at ... "Leveraging Information Technology to Meet Today,s,Healthcare Challenges" ...
... 23 MediCepts, Inc. is pleased,to announce Corso ... practice in New York State to offer the ... neck and back pain,patients. Owned and operated by ... MS,PT, Corso Rehabilitation and Physical Therapy Associates provides,outstanding ...
... American Idol Ice Cream and, Limited-edition CD at Participating Stop & Shop ... ... Calif., April 23 Everyone,s a,winner when you stop into participating Stop ... the Triple Winner Game,Scoop(R) Day event., This year, EDY,S Grand Ice ...
... Francisco,s Historic Dining Room for the Poor, SAN FRANCISCO, ... has no choice but to carefully utilize every resource it,has. ... and composting, St. Anthony,s offers 2,600 sustainably managed,healthy and filling ... of 33,cents per serving; and at no cost to the ...
Cached Medicine News:Health News:Sleep Apnea Screening Cuts Surgical Complications 2Health News:The Quantum Group CEO to Deliver Keynote Address at EDC Life Science Conference 2Health News:The Quantum Group CEO to Deliver Keynote Address at EDC Life Science Conference 3Health News:The Future of Spine Care Has Just Gotten Better With the Use of SpineSix BioMotion Spinal System(TM) 2Health News:EDY'S(R) Slow Churned(R) and Stop & Shop Stores Announce Scoop Day With Sweet Deals to Support the Fight Against Childhood Cancer 2Health News:The Greening of St. Anthony's 2
... Durable ergonomic chairs with concave seats ... • Select options like seats, backrests, ... Choose the BE Series for top ... including: industry, education, laboratory, clean room, ...
... ergonomic chairs with concave seats and large ... like seats, backrests, armrests, and casters and ... top performance in a variety of environments ... control, health care and office. • With ...
... Durable ergonomic chairs with concave seats and ... options like seats, backrests, armrests, and casters ... for top performance in a variety of ... static control, health care and office. • ...
... with concave seats and large backrests ... like seats, backrests, armrests, and casters ... Series for top performance in a ... laboratory, clean room, static control, health ...
Medicine Products: